Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 666

1.

Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance.

Pearson A, Proszek PZ, Pascual J, Fribbens C, Shamsher MK, Kingston B, O'Leary B, Herrera-Abreu MT, Cutts RJ, Garcia-Murillas I, Bye H, Walker BA, Gonzalez De Castro D, Yuan L, Jamal S, Hubank M, López-Knowles E, Schuster EF, Dowsett M, Osin P, Nerurkar A, Parton M, Okines AF, Johnston SRD, Ring A, Turner NC.

Clin Cancer Res. 2019 Oct 7. pii: clincanres.4044.2018. doi: 10.1158/1078-0432.CCR-18-4044. [Epub ahead of print]

PMID:
31591187
2.

Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors.

Leal MF, Haynes BP, Schuster EF, Yeo B, Afentakis M, Zabaglo L, Martins V, Buus R, Dodson A, Cheang MCU, Smith IE, Martin LA, Dowsett M.

Clin Cancer Res. 2019 Sep 23. pii: clincanres.1129.2019. doi: 10.1158/1078-0432.CCR-19-1129. [Epub ahead of print]

PMID:
31548345
3.

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC.

JAMA Oncol. 2019 Aug 1. doi: 10.1001/jamaoncol.2019.1838. [Epub ahead of print]

PMID:
31369045
4.

Asking young Aboriginal people who use illicit drugs about their healthcare preferences using audio-computer-assisted self-interviewing.

Dowsett M, Islam MM, Ganora C, Day C, Lee KSK, Dawson A, Joseph T, White A, Freeburn B, Conigrave KM.

Drug Alcohol Rev. 2019 Jul;38(5):482-493. doi: 10.1111/dar.12957.

PMID:
31317595
5.

Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry.

Woolf DK, Li SP, Detre S, Liu A, Gogbashian A, Simcock IC, Stirling J, Kosmin M, Cook GJ, Siddique M, Dowsett M, Makris A, Goh V.

Biomark Cancer. 2019 Jun 4;11:1179299X19851513. doi: 10.1177/1179299X19851513. eCollection 2019.

6.

Reply to J.A. Sparano et al.

Dowsett M, Turner N.

J Clin Oncol. 2019 Jul 20;37(21):1842. doi: 10.1200/JCO.19.01147. Epub 2019 Jun 7. No abstract available.

PMID:
31173555
7.

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG).

Histopathology. 2019 Aug;75(2):225-235. doi: 10.1111/his.13880. Epub 2019 Jul 8.

PMID:
31017314
8.

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C, Easton DF, Sherman ME, Garcia-Closas M, Dowsett M, Pharoah PD.

Mod Pathol. 2019 Sep;32(9):1244-1256. doi: 10.1038/s41379-019-0270-4. Epub 2019 Apr 11.

9.

Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach.

Leal MF, Haynes BP, MacNeill FA, Dodson A, Dowsett M.

Breast Cancer Res Treat. 2019 Jun;175(2):317-326. doi: 10.1007/s10549-019-05163-6. Epub 2019 Feb 22.

10.

Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.

Dowsett M, Turner N.

J Clin Oncol. 2019 Mar 20;37(9):689-692. doi: 10.1200/JCO.18.01412. Epub 2019 Feb 11. No abstract available.

PMID:
30742561
11.

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber RD, Dowsett M, Leyland-Jones B, Piccart-Gebhart MJ, DE Azambuja E.

Anticancer Res. 2019 Feb;39(2):797-802. doi: 10.21873/anticanres.13177.

PMID:
30711959
12.

In Reply.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M.

Arch Pathol Lab Med. 2019 Apr;143(4):413-414. doi: 10.5858/arpa.2018-0906-LE. Epub 2019 Jan 3. No abstract available.

PMID:
30605367
13.

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.

Lopez-Knowles E, Pearson A, Schuster G, Gellert P, Ribas R, Yeo B, Cutts R, Buus R, Garcia-Murillas I, Haynes B, Martin LA, Smith I, Turner N, Dowsett M.

Br J Cancer. 2019 Jan;120(2):247-255. doi: 10.1038/s41416-018-0345-x. Epub 2018 Dec 19.

14.

Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.

Richman J, Dowsett M.

Nat Rev Clin Oncol. 2019 May;16(5):296-311. doi: 10.1038/s41571-018-0145-5. Review.

PMID:
30563978
15.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA.

J Clin Oncol. 2019 Jan 20;37(3):178-189. doi: 10.1200/JCO.18.01624. Epub 2018 Dec 6.

PMID:
30523750
16.

Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer.

Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, Fronick C, Cook L, Snider JE, Davies S, Kavuri SM, Chang EC, Magrini V, Larson DE, Fulton RS, Liu S, Leung S, Voduc D, Bose R, Dowsett M, Wilson RK, Nielsen TO, Mardis ER, Ellis MJ.

Nat Commun. 2018 Nov 14;9(1):4850. doi: 10.1038/s41467-018-07407-3.

17.

Reply to C. Murray et al and V. Martin et al.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M.

J Clin Oncol. 2018 Oct 22:JCO1801163. doi: 10.1200/JCO.18.01163. [Epub ahead of print] No abstract available.

PMID:
30346904
18.

Circulating Growth and Sex Hormone Levels and Breast Tissue Composition in Young Nulliparous Women.

Denholm R, De Stavola BL, Hipwell JH, Doran SJ, Holly JMP, Folkerd E, Dowsett M, Leach MO, Hawkes DJ, Dos-Santos-Silva I.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1500-1508. doi: 10.1158/1055-9965.EPI-18-0036. Epub 2018 Sep 18.

PMID:
30228153
19.

The prognostic effects of somatic mutations in ER-positive breast cancer.

Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, Fronick C, Cook L, Snider JE, Davies S, Kavuri SM, Chang EC, Magrini V, Larson DE, Fulton RS, Liu S, Leung S, Voduc D, Bose R, Dowsett M, Wilson RK, Nielsen TO, Mardis ER, Ellis MJ.

Nat Commun. 2018 Sep 4;9(1):3476. doi: 10.1038/s41467-018-05914-x. Erratum in: Nat Commun. 2018 Nov 14;9(1):4850.

20.

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M.

Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9.

21.

An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer.

Rimm DL, Leung SCY, McShane LM, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere EK, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga EN, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M.

Mod Pathol. 2019 Jan;32(1):59-69. doi: 10.1038/s41379-018-0109-4. Epub 2018 Aug 24.

PMID:
30143750
22.

Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.

Dodson A, Parry S, Ibrahim M, Bartlett JM, Pinder S, Dowsett M, Miller K.

J Pathol Clin Res. 2018 Oct;4(4):262-273. doi: 10.1002/cjp2.112. Epub 2018 Sep 21.

23.

Exploring the scope of capacitance-assisted electrochemical carbon dioxide capture.

Dowsett MR, Lewis CM, North M, Parkin A.

Dalton Trans. 2018 Aug 21;47(31):10447-10452. doi: 10.1039/c8dt01783b. Epub 2018 Jul 19.

PMID:
30022187
24.

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.

Simigdala N, Pancholi S, Ribas R, Folkerd E, Liccardi G, Nikitorowicz-Buniak J, Johnston SR, Dowsett M, Martin LA.

Br J Cancer. 2018 Aug;119(3):313-322. doi: 10.1038/s41416-018-0158-y. Epub 2018 Jul 11.

25.

Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.

Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, Huang Y, Geradts J, Jiang P, Fei T, Chi D, Zang C, Liao Q, Rennhack J, Andrechek E, Li N, Detre S, Dowsett M, Jeselsohn RM, Liu XS, Brown M.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7869-7878. doi: 10.1073/pnas.1722617115. Epub 2018 Jul 9.

26.

HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M.

J Oncol Pract. 2018 Jul;14(7):437-441. doi: 10.1200/JOP.18.00206. Epub 2018 Jun 19. No abstract available.

PMID:
29920138
27.

The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer.

Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, Trahearn N, Hrebien S, Garcia-Murillas I, Chkhaidze K, Ermini L, Huntingford IS, Cottom H, Zabaglo L, Koelble K, Khalique S, Rusby JE, Muscara F, Dowsett M, Maley CC, Natrajan R, Yuan Y, Schiavon G, Turner N, Sottoriva A.

Clin Cancer Res. 2018 Oct 1;24(19):4763-4770. doi: 10.1158/1078-0432.CCR-17-3374. Epub 2018 Jun 11.

28.

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dowsett M, Johnston SR, Martin LA.

Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1.

29.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.

PMID:
29846122
30.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA. Epub 2018 May 30.

PMID:
29846104
31.

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.

Gao Q, López-Knowles E, U Cheang MC, Morden J, Ribas R, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Evans A, Bliss JM, Robertson J, Smith I, Martin LA, Dowsett M; POETIC Trial Management Group and Trialists.

JNCI Cancer Spectr. 2018 May 22;2(2):pky005. doi: 10.1093/jncics/pky005. eCollection 2018 Apr.

32.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

33.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.

34.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

35.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

36.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

37.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M.

JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524.

38.

SNPs for breast cancer risk assessment.

Cuzick J, Brentnall A, Dowsett M.

Oncotarget. 2017 Nov 3;8(59):99211-99212. doi: 10.18632/oncotarget.22278. eCollection 2017 Nov 21. No abstract available.

39.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Quang LH, Han PT, Khoa PH, Dinh NV, To TV, Clemons M, Smith IE, Dowsett M.

NPJ Breast Cancer. 2017 Nov 27;3:47. doi: 10.1038/s41523-017-0049-z. eCollection 2017.

40.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M.

Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y.

41.

Capacitance-Assisted Sustainable Electrochemical Carbon Dioxide Mineralisation.

Lamb KJ, Dowsett MR, Chatzipanagis K, Scullion ZW, Kröger R, Lee JD, Aguiar PM, North M, Parkin A.

ChemSusChem. 2018 Jan 10;11(1):137-148. doi: 10.1002/cssc.201702087. Epub 2017 Dec 12.

42.

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.

Dodson A, Okonji D, Assersohn L, Rigg A, Sheri A, Turner N, Smith I, Parton M, Dowsett M.

Breast Cancer Res Treat. 2018 Feb;168(1):249-258. doi: 10.1007/s10549-017-4514-z. Epub 2017 Nov 11.

43.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG.

N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.

44.

RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.

Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M, Cuzick JM, Greenhalgh R, Boggis C, Motion J, Sergeant JC, Adams J, Evans DG.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):58-66. doi: 10.1158/1055-9965.EPI-17-0158. Epub 2017 Nov 2.

45.

Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women.

Farland LV, Mu F, Eliassen AH, Hankinson SE, Tworoger SS, Barbieri RL, Dowsett M, Pollak MN, Missmer SA.

Cancer Causes Control. 2017 Dec;28(12):1441-1452. doi: 10.1007/s10552-017-0971-2. Epub 2017 Oct 31.

46.

Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.

Lawler K, Papouli E, Naceur-Lombardelli C, Mera A, Ougham K, Tutt A, Kimbung S, Hedenfalk I, Zhan J, Zhang H, Buus R, Dowsett M, Ng T, Pinder SE, Parker P, Holmberg L, Gillett CE, Grigoriadis A, Purushotham A.

Breast Cancer Res. 2017 Oct 13;19(1):113. doi: 10.1186/s13058-017-0881-y.

47.

Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.

Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx137.

48.

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkerd E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH, Dowsett M.

Oncologist. 2017 Sep;22(9):1028-1038. doi: 10.1634/theoncologist.2017-0072. Epub 2017 Jun 26.

49.

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.

Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4482-E4491. doi: 10.1073/pnas.1620993114. Epub 2017 May 15.

50.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).

Eur J Cancer. 2017 Jul;79:129-138. doi: 10.1016/j.ejca.2017.03.033. Epub 2017 May 8.

PMID:
28494403

Supplemental Content

Loading ...
Support Center